Bruce Barclay

Surmodics signs licensing deal with Australian drug firm

SurModics Inc. (Nasdaq: SRDX) has reached a deal to license its drug delivery technology to an Australian firm that will use it for a skin disorder treatment. Clinuvel Pharmaceuticals Ltd. of Melbourne will use SurModics’ polymer implant technology for a drug called Scenesse, according to a statement from SurModics. SurModics’ technology will allow the drug […]

By Brandon Glenn

News

SurModics future uncertain after CEO leaves drug delivery company

You certainly can’t accuse Bruce Barclay of standing still. Since SurModics Inc. (NASDAQ: SRDX) named Barclay CEO in 2005, Barclay has reorganized the drug company’s business units, purchased land, signed licensing agreements, acquired several companies and expanded into ophthalmology and drug development. Yet the company, based in Eden Prairie, Minn., still has little to show […]

By Thomas Lee

Consultants: Help Define What’s Next In Healthcare Benefits

Help shape the future of healthcare benefits by sharing your insights.

By MedCity News

Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options

FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.

By FASENRA, Sponsored Content

Tackling Rising Drug Costs and Growing Popularity of GLP-1’s

See how Quantum Health is providing the steps to help their members tackle the cost of specialty medications and other drugs.

By Quantum Health and MedCity News

Artificial Intelligence

Why Your Patients Are Leaving and How to Stop It

Patient expectations continue to evolve, and healthcare practices that fail to adapt risk more than just revenue—they risk losing trust.

By Bryan Sequeira, Director, Product Management Greenway Health